Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > AstraZeneca Tipped to Buy U.S. Group Forest as it Loses Seroquel Patent Case

FDAnews Drug Daily Bulletin

March 26, 2012 | Vol. 9 No. 60

AstraZeneca Tipped to Buy U.S. Group Forest as it Loses Seroquel Patent Case

AstraZeneca could be on the acquisition trail, analysts believe, with U.S. group Forest Laboratories tipped as a prime target.
The Guardian

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Full Issue Correction Astellas Scraps EU Marketing Plans for Kidney Cancer Candidate Merck Ends Trials For Once-Promising Parkinson’s Drug

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.